DUTCH ASSET Corp purchased a new stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 4,323 shares of the exchange traded fund’s stock, valued at approximately $527,000.
Several other institutional investors have also modified their holdings of XBI. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of SPDR S&P Biotech ETF during the 4th quarter valued at $27,000. Intesa Sanpaolo Wealth Management acquired a new position in shares of SPDR S&P Biotech ETF in the 4th quarter worth $30,000. SHP Wealth Management acquired a new position in shares of SPDR S&P Biotech ETF in the 4th quarter worth $31,000. Legacy Wealth Managment LLC ID acquired a new stake in shares of SPDR S&P Biotech ETF during the fourth quarter worth $32,000. Finally, Smartleaf Asset Management LLC acquired a new stake in shares of SPDR S&P Biotech ETF during the fourth quarter worth $32,000.
SPDR S&P Biotech ETF Stock Performance
XBI opened at $140.72 on Friday. The firm has a market cap of $8.98 billion, a P/E ratio of 11.47 and a beta of 0.85. The business has a 50 day moving average price of $133.56 and a 200 day moving average price of $127.70. SPDR S&P Biotech ETF has a twelve month low of $80.90 and a twelve month high of $143.46.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
See Also
- Five stocks we like better than SPDR S&P Biotech ETF
- Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself?
- Rackspace’s AI Land Grab: Plugging Into the Next Compute Boom
- Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore
- Why Kroger’s Pullback Could Be a Gift for Patient Investors
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
